Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Coya Therapeutics, Inc. Common Stock (COYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: COYA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -28.26% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 109.72M USD | Price to earnings Ratio - | 1Y Target Price 16.1 |
Price to earnings Ratio - | 1Y Target Price 16.1 | ||
Volume (30-day avg) 117745 | Beta 0.32 | 52 Weeks Range 4.75 - 10.24 | Updated Date 04/1/2025 |
52 Weeks Range 4.75 - 10.24 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Earnings Date
Report Date 2025-03-18 | When - | Estimate -0.14 | Actual -0.18 |
Profitability
Profit Margin - | Operating Margin (TTM) -209031.5% |
Management Effectiveness
Return on Assets (TTM) -25.15% | Return on Equity (TTM) -39.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 69870975 | Price to Sales(TTM) 30.87 |
Enterprise Value 69870975 | Price to Sales(TTM) 30.87 | ||
Enterprise Value to Revenue 19.66 | Enterprise Value to EBITDA -6.21 | Shares Outstanding 16725000 | Shares Floating 12564320 |
Shares Outstanding 16725000 | Shares Floating 12564320 | ||
Percent Insiders 7.03 | Percent Institutions 26.69 |
Analyst Ratings
Rating 4.8 | Target Price 15.5 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Coya Therapeutics, Inc. Common Stock
Company Overview
History and Background
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative cell-based therapies to treat neurodegenerative diseases, autoimmune diseases and cancer.
Core Business Areas
- Cell-Based Therapeutics: Developing and commercializing cell-based therapies, including Treg-based therapies, for neurodegenerative diseases (ALS, MS), autoimmune diseases and cancer.
Leadership and Structure
Dr. Howard Berman is CEO. The company has a board of directors and various management positions overseeing clinical development, research, and operations.
Top Products and Market Share
Key Offerings
- COYA 101: An autologous Treg cell therapy being investigated for Amyotrophic Lateral Sclerosis (ALS). Currently in clinical trials. Competitors: Biogen (Tofersen), Amylyx Pharmaceuticals (Relyvrio).
- COYA 206: A novel, engineered IL-2 Treg potentiating antibody being developed for autoimmune diseases. Currently in preclinical stage. Competitors: Various companies developing Treg-modulating therapies.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunology and genetic engineering. Significant unmet needs remain in neurodegenerative and autoimmune diseases, creating opportunities for innovative therapies.
Positioning
Coya Therapeutics is positioned as an innovator in Treg-based therapies, focusing on diseases with limited treatment options. Its competitive advantage lies in its novel approach to modulating the immune system.
Total Addressable Market (TAM)
The TAM for ALS and autoimmune diseases is estimated to be in the billions of dollars. Coya is positioned to capture a significant share of this market with successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Novel Treg-based therapy platform
- Experienced leadership team
- Proprietary technologies
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- High R&D costs
- Early stage development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new disease areas
- Positive clinical trial results
- Regulatory approval and commercialization
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- BIOGEN (BIIB)
- AMYLYX PHARMACEUTICALS, INC. (AMLX)
- BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
Competitive Landscape
Coya competes with established pharmaceutical companies and other biotech firms in the neurodegenerative and autoimmune disease spaces. Coya's novel Treg approach sets it apart, but it faces challenges in competing with larger, better-funded companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical studies through clinical trials.
Future Projections: Future growth is dependent on successful clinical trials and subsequent commercialization of its therapies. Analyst estimates vary widely.
Recent Initiatives: Advancing clinical trials for COYA 101 and preclinical development of COYA 206 are key recent initiatives.
Summary
Coya Therapeutics is a high-risk, high-reward biotechnology company focused on innovative Treg-based therapies. Their success hinges on positive clinical trial outcomes and securing funding to advance their pipeline. The company faces strong competition but has a novel approach that could address unmet medical needs. Investors should closely monitor clinical trial results and financial stability.
Similar Companies
- BCLI
- MESO
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10K, 10Q)
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coya Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-12-29 | CEO & Director Dr. Arun Swaminathan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.coyatherapeutics.com |
Full time employees 8 | Website https://www.coyatherapeutics.com | ||
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.